Stocks Are Taking a Hit Once More, But There's No Need to Panic.

Written by Emily J. Thompson, Senior Investment Analyst

GEHC-2.59%

NXPI-1.81%

DE-1.52%

Source: Barron's

Updated: Nov 18 2025

0mins

Source: Barron's

Market Condition: The stock market is experiencing a slowdown, but it is not in a severe downturn.
Investor Sentiment: Investors are expressing concerns regarding the valuations of leading tech and artificial intelligence stocks.

GEHC

$79.77+Infinity%1D

Analyst Views on GEHC

Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is 92.25 USD with a low forecast of 80.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Analyst Rating

8 Buy

5 Hold

0 Sell

Moderate Buy

Current: 81.890

Low

80.00

Averages

92.25

High

105.00

Current: 81.890

Low

80.00

Averages

92.25

High

105.00

Jefferies

Jay Saccaro

maintain

$95 -> $105

2025-12-11

Reason

Jefferies

Jay Saccaro

Price Target

$95 -> $105

AI Analysis

2025-12-11

maintain

Reason

Jefferies raised the firm's price target on GE HealthCare to $105 from $95 and keeps a Buy rating on the shares after having hosted a call with CFO Jay Saccaro and other executives. The firm, which was "encouraged" by GE HealthCare's Q3 performance and leading indicators, sees stable to improving fundamentals and "a strong catalyst path" with consensus appearing to model very little contribution from Flyrcado or Vizamyl/Cerianna, the analyst tells investors.

Citi

Neutral

maintain

$83 -> $88

2025-12-11

Reason

Citi

Price Target

$83 -> $88

2025-12-11

maintain

Neutral

Reason

Citi raised the firm's price target on GE HealthCare to $88 from $83 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GEHC

Unlock Now

Wells Fargo

Larry Biegelsen

Overweight

maintain

$89 -> $87

2025-10-30

Reason

Wells Fargo

Larry Biegelsen

Price Target

$89 -> $87

2025-10-30

maintain

Overweight

Reason

Wells Fargo analyst Larry Biegelsen lowered the firm's price target on GE HealthCare to $87 from $89 and keeps an Overweight rating on the shares. The firm notes the company delivered a beat on the top line and EPS of $1.07 was ahead of both consensus and Wells Fargo's estimates. EBIT margins were down 150bps year-over-year, but above the firm's estimates. GE HealthCa raised the lower end of 2025 EPS guidance, but Flyrcado to be less than $30M in 2025 sales.

Morgan Stanley

Patrick Wood

Equal Weight

maintain

$74 -> $80

2025-10-29

Reason

Morgan Stanley

Patrick Wood

Price Target

$74 -> $80

2025-10-29

maintain

Equal Weight

Reason

Morgan Stanley analyst Patrick Wood raised the firm's price target on GE HealthCare to $80 from $74 and keeps an Equal Weight rating on the shares. The firm said it updated its model for Q3 earnings, which were slightly above expectations. Demand is looking solid for GE HealthCare, with solid order backlog and peer results, and the firm's hospital CapEx survey suggests a healthy environment, the analyst tells investors in a research note. The analyst added that it equally believes mid-term margin targets are sensible and sees upside risk long-term from photon counting.

About GEHC

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.